Literature DB >> 35284104

Nomogram for the prediction of lymph node metastasis and survival outcomes in rectal neuroendocrine tumour patients undergoing resection.

Qichen Chen1, Jinghua Chen1, Yiqiao Deng1, Yizhou Zhang1, Zhen Huang1, Hong Zhao1, Jianqiang Cai1.   

Abstract

Background: The current study analysed rectal neuroendocrine tumour (RNET) patients undergoing resection to identify predictive factors and construct nomograms for lymph node metastasis, cancer-specific survival (CSS) and overall survival (OS).
Methods: RNET patients registered in the Surveillance, Epidemiology, and End Results (SEER) database were included in this study. Multivariable logistic regression analysis was used to investigate the relationships between clinicopathological factors and lymph node metastasis. A multivariate competing risk model was applied to investigate factors independently associated with CSS. Through the Cox regression model, a multivariable analysis of OS was performed. Nomograms were established based on independent predictive factors. Calibration plots, receiver operating characteristic (ROC) curves and Brier scores were used to evaluate the predictive accuracy of the nomograms.
Results: In this study, 1,253 RNET patients were included for further analysis. Tumour size ≥12 mm (P<0.001), T3/T4 stage (P<0.001) and M1 stage (P=0.001) were independently associated with lymph node metastasis. The performance of the nomogram was acceptable for predicting lymph node metastasis, with an area under the ROC curve (AUC) of 0.937 [95% confidence interval (CI): 0.874-1.000]. Calibration curves and the Hosmer-Lemeshow test revealed desirable model calibration (P=0.99996). The multivariate competing risk model analysis showed that grade II (P=0.017), tumour size ≥12 mm (P=0.007), AJCC TNM stage II (P=0.002), stage III (P<0.001) and stage IV (P<0.001) were significantly associated with worse CSS. In the competing risk nomogram model, the time-dependent AUC revealed good discriminatory ability of the model (time from 1 to 107 months, AUC >0.900), and the Brier score showed good accuracy of the nomogram, which was greater than that of the AJCC TNM stage. Multivariate Cox analysis showed that age >60 years (P=0.002), median income ≥$65,000 (P=0.013), AJCC TNM stage III (P=0.038) and AJCC TNM stage IV (P<0.001) were independently associated with worse OS. In the nomogram for the prediction of OS, the C-statistic was 0.703 (95% CI: 0.615-0.792), which was significantly better than that of the AJCC TNM stage (0.703 vs. 0.607, P=0.009). A calibration plot for the probability of survival demonstrated good calibration. Conclusions: The present study is the first to establish nomograms with great discrimination and accuracy for the prediction of lymph node metastases, CSS and OS in RNET patients, which can be used to guide treatment decision-making and surveillance. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Rectal neuroendocrine tumours (RNETs); Surveillance, Epidemiology, and End Results (SEER); lymph node metastasis; nomogram; survival

Year:  2022        PMID: 35284104      PMCID: PMC8899747          DOI: 10.21037/jgo-21-573

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  14 in total

1.  Local Excision Versus Radical Resection for 1- to 2-cm Neuroendocrine Tumors of the Rectum: A National Cancer Database Analysis.

Authors:  Adam C Fields; Lily V Saadat; Rebecca E Scully; Jennifer S Davids; Joel E Goldberg; Ronald Bleday; Nelya Melnitchouk
Journal:  Dis Colon Rectum       Date:  2019-04       Impact factor: 4.585

Review 2.  The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines.

Authors:  Wouter T Zandee; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2018-01-10       Impact factor: 4.914

Review 3.  Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors.

Authors:  Louis de Mestier; Diane Lorenzo; Caroline Fine; Jérôme Cros; Olivia Hentic; Thomas Walter; Yves Panis; Anne Couvelard; Guillaume Cadiot; Philippe Ruszniewski
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2019-07-09       Impact factor: 4.690

4.  Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors.

Authors:  Beonghoon Sohn; Yoomin Kwon; Seung-Bum Ryoo; Inho Song; Yoon-Hye Kwon; Dong Woon Lee; Sang Hui Moon; Ji Won Park; Seung-Yong Jeong; Kyu Joo Park
Journal:  J Gastrointest Surg       Date:  2017-10-18       Impact factor: 3.452

5.  Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score.

Authors:  Nick J Battersby; George Bouliotis; Katrine J Emmertsen; Therese Juul; Rob Glynne-Jones; Graham Branagan; Peter Christensen; Søren Laurberg; Brendan J Moran
Journal:  Gut       Date:  2017-01-23       Impact factor: 23.059

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

8.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

9.  Nomogram for individually predicting overall survival in rectal neuroendocrine tumours.

Authors:  Xingyu Feng; Gengzhou Wei; Wei Wang; Yu Zhang; Yujie Zeng; Minhu Chen; Ye Chen; Jie Chen; Zhiwei Zhou; Yong Li
Journal:  BMC Cancer       Date:  2020-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.